$28.89—
NASDAQ
$28.89—
Fidelity Select Biotechnology Portfolio (FBIOX) is a mutual fund focused on investing in biotechnology companies, primarily in the United States. Its competitive position is bolstered by Fidelity's extensive research capabilities and a diversified portfolio that includes leading biotech firms engaged in drug development and innovative therapies.
FBIOX generates revenue primarily through management fees based on the total assets under management. The fund's focus on biotechnology allows it to leverage Fidelity's research and analytical capabilities, providing investors with access to high-growth potential companies in the biotech sector.
Performance of underlying biotech stocks, particularly those in clinical trials or with FDA approvals
Changes in healthcare regulations affecting biotech investments
Market sentiment towards risk assets, particularly in the healthcare sector
Advancements in biotechnology that lead to new investment opportunities
Regulatory changes that could impact drug approval processes and market access
Technological disruption in drug development methodologies
Emerging biotech funds with lower fees or better performance
Increased competition from passive investment vehicles targeting biotech
Potential liquidity risks if significant redemptions occur
Market volatility impacting the valuation of biotech investments
moderate - The biotech sector can be sensitive to economic cycles, as funding for biotech innovations may fluctuate with overall market conditions and investor sentiment.
Higher interest rates can lead to increased borrowing costs for biotech firms, potentially impacting their valuations and the attractiveness of biotech investments.
minimal - The fund is not directly dependent on credit markets, but the financial health of biotech companies can be influenced by credit conditions.
growth - Investors looking for high-growth potential in the biotech sector are typically attracted to FBIOX.
high - The fund's performance can be volatile due to the inherent risks associated with biotech investments.